Why the study?
The optimal choice of antithrombotic therapy (anticoagulants or antiplatelets) following prosthetic heart valve replacement or repair remains a disputed topic in the literature.
Does antithrombotic therapy reduce thromboembolic events in patients with prosthetic heart valves?
Does antithrombotic therapy reduce thromboembolic events in patients with prosthetic heart valves?
This review summarizes the available literature on antithrombotic therapies for patients with prosthetic heart valves to assist clinical decision-making.
Answers are grounded in this paper and cite their sources.
Provides synthesis of antithrombotic options for prosthetic valves to inform decisions; leaves open optimal regimens pending prospective trials.
BACKGROUND: The choice of antithrombotic therapy, anticoagulants or antiplatelets, after prosthetic heart valve replacement or repair, remains a disputed topic in the literature. Antithrombotic therapies are used after heart valve intervention to reduce the rates of thromboembolic events, therefore improving patient outcomes. Different interventions may require different therapeutic regimens to achieve the most efficacious clinical outcome for patients. METHODS AND DISCUSSION: This review aims to summarize and critique the available literature concerning therapeutic agents used for bioprosthetic and mechanical valves as well as for valve repair, so as to assist clinicians and researchers in making decisions with regard to their patients and research endeavors.
No takes yet. Share an insight, caveat, or question.
Aikins et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: